- Medical Education - Research Publications
Medical Education - Research Publications
Permanent URI for this collection
Search Results
Now showing
1 - 9 of 9
-
ItemNo Preview AvailableIn-hospital hyperglycaemia but not diabetes mellitus alone is associated with increased in-hospital mortality in community-acquired pneumonia (CAP): a systematic review and meta-analysisBarmanray, R ; Cheuk, N ; Fourlanos, S ; Greenberg, P ; Colman, P ; Worth, L (University of Melbourne, 2022)
-
ItemNo Preview AvailablePregnancy planning in a woman with diabetes secondary to familial partial lipodystrophy due to a rare PPAR gamma gene variantGong, J ; Barmanray, R ; Nankervis, A ; Price, S ; Trainer, A ; Conn, J (International Association of the Diabetes and Pregnancy Study Groups, 2022)
-
ItemNo Preview AvailableDiabetes Digital Phenotyping to Improve Documentation of Diabetes in Hospital InpatientsBarmanray, R ; Fazio, T ; Sharma, A ; Grundy, L ; KITT-THOMPSON, T ; Coote, A ; Bode, G ; PLUMB, S (Australian Diabetes Society, 2022)
-
ItemNo Preview AvailableThe Specialist Treatment of Inpatients: Caring for Diabetes (STOIC-D) Surgery Randomised Controlled Trial – Proactive Electronic-based Care Reduces Glucose and Healthcare-Associated InfectionsBarmanray, R ; Kyi, M ; Colman, P ; Rowan, L ; Raviskanthan, M ; Collins, L ; Donaldson, L ; Tsan, J ; Sun, E ; Le, M ; Worth, L ; Fourlanos, S (Australian Diabetes Society, 2022)
-
ItemNo Preview AvailableThe Diabetes IN hospital – Glucose and Outcomes in the COVID-19 pandemic (DINGO COVID-19) study: the 2020 Melbourne hospital experience prior to vaccination programs and the delta variantBarmanray, R ; Gong, J ; Kyi, M ; Kevat, D ; Islam, M ; Galligan, A ; Manos, G ; Perera, N ; Adams, N ; Nursing, A ; Warren, A ; Hamblin, P ; MacIsaac, R ; Ekinci, E ; Krishnamurthy, B ; Nair, I ; Karunajeewa, H ; Buising, K ; Visvanathan, K ; Kay, T ; Fourlanos, S (Australian Diabetes Society, 2022)
-
ItemNo Preview AvailableOvernight hospital admission is associated with healthcare-associated infection but not adverse glycaemia in patients undergoing glucose monitoring in the DINGO studySun, E ; Hazara, A ; Barmanray, R ; Kyi, M ; Fourlanos, S (Australian Diabetes Society, 2022)
-
ItemNo Preview AvailableLower socioeconomic status is not associated with adverse glycaemia in hospital inpatients, The Diabetes IN-hospital: Glucose and Outcomes and Socioeconomic Status (DINGO-SES) studyHazara, A ; Sun, E ; Barmanray, R ; Kyi, M ; Fourlanos, S (Australian Diabetes Society, 2022)
-
ItemNo Preview AvailableIn-hospital hyperglycaemia but not diabetes mellitus alone is associated with increased in-hospital mortality in community-acquired pneumonia (CAP): a systematic review and meta-analysisBarmanray, R ; Cheuk, N ; Fourlanos, S ; Greenberg, P ; Colman, P ; Worth, L (Australian Diabetes Society, 2022)
-
ItemNo Preview AvailableGlycaemic outcomes in hospital with IDegAsp vs. BIAsp30 premixed insulinsWalt, J ; Loughran, J ; Fourlanos, S ; Barmanray, R ; Zhu, J ; Varadarajan, S (Australian Diabetes Society, 2022)BACKGROUND AND AIMS: IDegAsp (Ryzodeg 70/30), a unique premixed formulation of long-acting insulin degludec and rapid-acting insulin aspart, is increasing in use. Management of IDegAsp during hospitalisation is challenging because of degludec's ultra-long duration of action. We investigated inpatient glycaemia in patients treated with IDegAsp compared to biphasic insulin aspart (BIAsp30; Novomix30). METHODS: We performed a retrospective observational study at two hospitals assessing inpatients with type 2 diabetes treated with IDegAsp or BIAsp30 prior to and during hospital admission. Standard inpatient glycaemic outcomes were analysed based on capillary blood glucose (BG) measurements. RESULTS: We assessed 88 individuals treated with IDegAsp and 88 HbA1c-matched individuals treated with BIAsp30. Patient characteristics, including insulin dose at admission, were well matched, but the IDegAsp group had less frequent twice-daily insulin dosing than the BIAsp30 group (49% vs 87%, P < 0.001). Patient-days with BG <4 mmol/L were not different (10.6% vs 9.9%, P = 0.7); however, the IDegAsp group had a higher patient-day mean BG (10.4 (SD 3.4) vs 10.0 (3.4) mmol/L, P < 0.001), and more patient-days with mean BG >10 mmol/L (48% vs 38%, P < 0.001) compared to the BIAsp30 group. Glucose was higher in the IDegAsp group in the evening (4 PM to midnight) (11.6 (SD 4.0) vs 10.9 (4.6) mmol/L, P = 0.004), but not different at other times during the day. CONCLUSIONS: Inpatients treated with IDegAsp compared to BIAsp30 had similar hypoglycaemia incidence, but higher hyperglycaemia incidence, potentially related to less frequent twice-daily dosing. With the increasing use of IDegAsp in the community, development of hospital management guidelines for this insulin formulation is needed.